IL281129A - Methods and compositions containing B7H3 chimeric antigen receptors - Google Patents

Methods and compositions containing B7H3 chimeric antigen receptors

Info

Publication number
IL281129A
IL281129A IL281129A IL28112921A IL281129A IL 281129 A IL281129 A IL 281129A IL 281129 A IL281129 A IL 281129A IL 28112921 A IL28112921 A IL 28112921A IL 281129 A IL281129 A IL 281129A
Authority
IL
Israel
Prior art keywords
compositions
methods
chimeric antigen
antigen receptors
receptors
Prior art date
Application number
IL281129A
Other languages
English (en)
Hebrew (he)
Inventor
Michael C Jensen
Adam Johnson
Original Assignee
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Michael C Jensen
Adam Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital Dba Seattle Childrens Res Inst, Michael C Jensen, Adam Johnson filed Critical Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Publication of IL281129A publication Critical patent/IL281129A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IL281129A 2018-08-31 2021-02-25 Methods and compositions containing B7H3 chimeric antigen receptors IL281129A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725599P 2018-08-31 2018-08-31
PCT/US2019/048814 WO2020047257A1 (en) 2018-08-31 2019-08-29 Methods and compositions comprising b7h3 chimeric antigen receptors

Publications (1)

Publication Number Publication Date
IL281129A true IL281129A (en) 2021-04-29

Family

ID=69643750

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281129A IL281129A (en) 2018-08-31 2021-02-25 Methods and compositions containing B7H3 chimeric antigen receptors

Country Status (8)

Country Link
US (2) US12173071B2 (enExample)
EP (1) EP3844191A4 (enExample)
JP (2) JP7627080B2 (enExample)
CN (1) CN113039206A (enExample)
AU (1) AU2019333149B2 (enExample)
CA (1) CA3110858A1 (enExample)
IL (1) IL281129A (enExample)
WO (1) WO2020047257A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
WO2024094165A1 (zh) * 2022-11-04 2024-05-10 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
WO2024106941A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3 키메라 항원 수용체 및 이의 용도
AU2024263454A1 (en) * 2023-04-24 2025-12-11 Elpis Biopharmaceuticals Armored anti-b7h3 car-t cells and uses thereof in cancer therapy
CN119454937A (zh) 2023-11-13 2025-02-18 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN119792297B (zh) * 2024-11-11 2026-05-05 中国人民解放军军事科学院军事医学研究院 PNP抑制剂Forodesine在治疗脑肿瘤中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3288569A4 (en) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
WO2020010239A1 (en) * 2018-07-06 2020-01-09 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptor polypeptides and methods of using same

Also Published As

Publication number Publication date
AU2019333149B2 (en) 2026-07-09
JP7627080B2 (ja) 2025-02-05
EP3844191A4 (en) 2022-06-15
JP2025066785A (ja) 2025-04-23
US20250136697A1 (en) 2025-05-01
US20210324083A1 (en) 2021-10-21
US12173071B2 (en) 2024-12-24
EP3844191A1 (en) 2021-07-07
WO2020047257A1 (en) 2020-03-05
JP2021534784A (ja) 2021-12-16
AU2019333149A1 (en) 2021-03-25
CA3110858A1 (en) 2020-03-05
CN113039206A (zh) 2021-06-25

Similar Documents

Publication Publication Date Title
IL275619A (en) Amplified chimeric antigen receptors and their uses
SG11202100205UA (en) Ror-1 specific chimeric antigen receptors and uses thereof
AU2016253126B2 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
IL277078A (en) Anti-CD33 chimeric antigen receptors and their uses
IL263626A (en) Chimeric antigen receptors and methods of use
IL278061A (en) Structures of antibodies against ROR
ZA201800703B (en) Chimeric antigen receptors based on single¿domain antibodies and methods of use thereof
SG11202100160SA (en) Uses of anti-bcma chimeric antigen receptors
SG11202000555UA (en) Chimeric antigen receptors (cars), compositions and methods thereof
IL255336A0 (en) Chimeric antigen receptors and methods of using them
ZA201705720B (en) Anti-dll3 chimeric antigen receptors and methods of use
SG11202009962UA (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
PT3674315T (pt) Recetores de antigénios quiméricos, composições e métodos
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL287487A (en) Chemical antigen receptors resistant to rituximab and their uses
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
SG11202108759SA (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
ZA202008065B (en) Muc16 specific chimeric antigen receptors and uses thereof
ZA201908245B (en) Transgenic macrophages, chimeric antigen receptors, and associated methods
SG11201606664UA (en) Chimeric antigen receptors and methods of making
IL275040A (en) T cells containing two chimeric receptors for different antigens and their use
EP3844191A4 (en) METHODS AND COMPOSITIONS USING CHIMERIC B7H3 ANTIGEN RECEPTORS
IL265438A (en) Chimeric antigen receptors and jewelry and methods of using them
GB2585607B (en) Chimeric antigen receptor and application thereof
HK40054343A (en) Methods and compositions comprising b7h3 chimeric antigen receptors